I do. I don’t think L helps the unmethylated GBM patient on its own. However, when you add in the adjuvant PolyICLC, it has a fighting chance. In the UCLA trial where the results were published in Nature, the unmethylated patients had a mOS of 28 or 29 months, so IMO, that’s a game changer. Obviously, reaching a cure is the goal, but this indicates they’re moving in a positive direction.
L offers the potential of a cure for methylated GBM, as those represent the patients from the P3 trial still alive today.
Market Data 
Markets 
AI
